Ilyang to conduct Phase 3 study on new leukemia drug

Published: 2011-05-31 06:58:00
Updated: 2011-05-31 06:58:00
Ilyang Pharmaceutical Co. says it will carry out its Phase III clinical trial for a new leukemia medicine IY5511.

The study is to be conducted for 250 leukemia patients in the chronic and accelerated phases of the disease for 12 months. Nine domestic hospitals and other foreign ones ― in Indon...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.